The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Investigating Immune Regulation In The Tumour Microenvironment
Funder
National Health and Medical Research Council
Funding Amount
$288,650.00
Summary
Suppressive factors made by cells of the immune system or cancers themselves and immune regulatory T cells inhibit an effective anti-tumour response. My project aims to investigate the mechanism by which these factors and cells mediate their suppressive function. Understanding these processes in the cancer environment will allow the design of more effective cancer therapies.
T Cell Trafficking And Effective Immunotherapy For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$218,807.00
Summary
Cancer is the major cause of death in Australia in 2007. New forms of treatment are needed. The body’s defences against infection can be harnessed to fight some cancers. This project will examine how we can do this better using the signals that tell the body’s killer cells where to go and what to do when they get there.
Perforin Trafficking And Activation In Killer Lymphocytes
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
Perforin (PRF) is a protein essential for the function of cytotoxic lymphocytes during an immune response in humans. Humans deficient in PRF are severely immunosuppressed and fall critically ill if they contract a viral infection. The partial loss of PRF function can also predispose an individual to cancer. We aim to investigate the functional and biochemical properties of PRF. The outcomes of this study will determine how PRF influences the immune system and immune homeostasis in humans.
The Characterisation Of Deubiquitinating Enzyme A (DUBA) In The Control Of Innate And Adaptive Immune Signalling.
Funder
National Health and Medical Research Council
Funding Amount
$396,041.00
Summary
In response to viruses, the immune system produces interferons. Interferons fight infections but can also contribute to autoimmune diseases, where the body mistakenly attacks itself. Production of interferons is regulated by DUBA. Thus DUBA is an attractive target for therapies against viruses or autoimmune diseases. To achieve this, it is important to understand not only the mechanism of action of DUBA, but also what other roles DUBA may play in the immune system. We can study these in mice.
Metagenomic Analysis To Determine The Prostate Microenvironment And The Aetiology Of Inflammatory Mediated Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$339,534.00
Summary
Infectious organisms have been implicated in the development of several different malignancies. This project aims to determine if this may also be applicable in prostate cancer and if so, to define which organism/s may be responsible, thus providing targets for improving diagnosis, treatment and prevention strategies. The approach will be to identify DNA in the prostate tumour tissue that is foreign to the �normal� prostate environment and indicative of an invading organism.
Deriving Actionable Strategies To Enhance Cancer Immunotherapy Response
Funder
National Health and Medical Research Council
Funding Amount
$447,193.00
Summary
Cancer immunotherapy is an increasingly common treatment used to treat several types of advanced cancers. Whilst it can be dramatically effective in a minority of patients, many patients do not respond to the treatment and our ability to predict who will not benefit is limited. This project aims to study distinct aspects of tumour immunology in patients receiving immunotherapy treatments in order to identify better predictors and more widely-effective immunotherapy treatment strategies.